Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.21.1
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Basic and diluted numerator:        
Net loss attributable to iBio, Inc. stockholders $ (7,661) $ (4,676) $ (23,323) $ (12,901)
Deemed dividends - down round of Series A Preferred and Series B Preferred     0 (21,560)
Preferred stock dividends – iBio CMO Preferred Tracking Stock (64) (65) (195) (196)
Net loss available to iBio, Inc. stockholders $ (7,725) $ (4,741) $ (23,518) $ (34,657)
Basic and diluted denominator:        
Weighted-average common shares outstanding 215,539 79,917 188,493 47,018
Per share amount $ (0.04) $ (0.06) $ (0.12) $ (0.74)